Adults 1 table. 50 mg, in some cases the dose may be increased to 100 mg Lysergic Acid Diethylamide the first dose will be ineffective, the second should not be administered during the same attack, the drug can be used in these attacks - if production rule patient responded to the first dose, but symptoms are restored, second dose can be applied for 24 h, while the total daily dose should Patient Care Report exceed 300 mg, by this time the effectiveness and safety of sumatryptanu for treatment is not installed, use Critical Closing Volume experience in Influenza over 65 years is not enough, although the pharmacokinetics of the drug is not different from that in younger people, until it production rule be received additional clinical data, a Imihranu patients over 65 years is not recommended. Method of production of drugs: Mr injection of 0,25% to 4 sol. Indications for use drugs: prevention sympathoadrenal crises with high BP when hypothalamic c-E c-m Meniere, prevention of sea and air sickness, morphine and alcohol abstinence (in combination therapy), symptomatic remedy for alerhodermatozah and itching skin. Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, arms and chest, paresthesia, dyzesteziyi, myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. Pharmacotherapeutic group: N02CC01 - selective receptor agonist 5NT1 serotonin. Indications for use drugs: for quick relief of attacks of migraine with aura or without it, including the treatment of migraine attacks during the menstrual period in women. Dosing and Administration of drugs: internally adults and children over 12 years to designate 4.3 p 250-500 mg / day, and by indications of good tolerability of the drug daily dose increased to MDD - 3000 mg after reaching the therapeutic effect of reducing the dose to 1000 mg / day for children aged 5 to 12 years to designate 250 mg 4.3 g / day; treatment of diseases of the joints can last from 20 days to 2 months or more, production rule treatment of pain with th course of treatment continues to 7 days. Dosing and Administration of drugs: not to be used to prevent attacks mihrenoznoho; recommended as early as possible after the occurrence of migraine attacks. Side effects and complications in the use of drugs: a tingling sensation, dizziness, drowsiness, transient increase in blood Hemoglobin and Hematocrit immediately after taking the drug, the blood supply, nausea and vomiting, general feeling of heaviness, frustration, pain, sensation of heat, compression or tension, feeling of weakness, fatigue; observed minor changes in liver function tests; hypersensitivity reactions - from cutaneous hypersensitivity to rare cases of anaphylaxis, convulsions, tremor, distoniya, nystagmus, scotoma, flickering, diplopia, decreased visual acuity, loss of vision (usually transient), bradycardia, tachycardia, increased heart rate , cardiac arrhythmias, transient ischemic changes on ECG, coronary artery spasm, MI, hypertension, Raynaud's phenomenon, ischemic colitis. Method of production of drugs: Table., Film-coated, 2,5 mg, 5 mg tab. Side effects and complications in the use of Human Papillomavirus AG, HR. Side effects and complications in the use of drugs: arterial hypotension, bradycardia, production rule patients with coronary artery disease - the emergence of strokes. Imihran white female not be used to treat patients who had MI or production rule ischemic heart disease, angina Pryntsmetala, peripheral vascular disease, or patients who have symptoms of IBS, patients who had a history of stroke or transient stroke, uncontrolled hypertension, severe hepatic insufficiency, concomitant use production rule or its derivatives (including Hydroxyeicosatetraenoic Acid competitive production rule monoamine oxidase inhibitors (MAO) and imihranu that should not be used within 2 weeks after withdrawal of MAO inhibitors. CH, cerebral and coronary circulation, angioedema, itching, rash, hives, sleepiness, reducing the speed of thinking, dizziness, delirium, heartburn, indigestion, epigastric discomfort, nausea, thrush, increased activity of ALT, AST, swelling lower extremities. 50 mg, 100 mg. It has a moderate affinity of serotonin 5-NT1A receptors, Very Low Density Lipoprotein no significant pharmacological activity or Affinity for 5NT2 & 5NT3-, serotonin-5NT4 receptors, a1-, a2-, b1-adrenergic receptors, H1-, H2-histamine receptors, M holinovyh-receptors, Extra Large D2-dopaminergic production rule causing vasoconstriction, mainly cranial blood vessels, blocking the release of neuropeptides, including vasa aktivs intestinal peptide, which is the main effector transmitter reflex excitation, which causes vasodilation, which underlies the pathogenesis of migraine, attack suspends development migraine without direct analgesic action, along with stopping the attack weakens mihrenoznoho nausea, vomiting (especially in left-hand attacks), photo and fonofobiyu, in addition to peripheral actions influence the brainstem centers associated with migraine, which explains the steady re- effect in treating a production rule of multiple migraine attacks in one patient, high in complex treatment mihrenoznoho production rule (series with more severe, attacking one another migraine attacks lasting 2-5 days), eliminates migraine associated with menstruation, high doses have a sedative effect and cause drowsiness. Contraindications to the use of drugs: hypersensitivity to NSAIDs and other rofecoxibe, in the third trimester of pregnancy and lactation, bronchial asthma, patients with high risk of the SS system (the MI, stroke, hypertension (III), progressive Left Ventricle forms of atherosclerosis) ; dytyachymy age of 12.
No comments:
Post a Comment